Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

ProQR licenses LUMC's antisense therapeutics IP for amyloid-beta-mediated diseases

Executive Summary

Dutch RNA-based therapeutics start-up ProQR Therapeutics NV licensed exclusive worldwide rights to Leiden University Medical Center's intellectual property to develop antisense therapeutics within the field of amyloid-beta related diseases, including Alzheimer’s disease (AD) and Katwijk’s disease (also known as HCHWA-D (hereditary cerebral hemorrhage with amyloidosis of the Dutch type)).
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Antisense, Oligonucleotides
    • Synthesis Technologies, Production Processes
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies